Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Organon Continues Building Women’s Health Portfolio With Forendo Buyout

Nov 11 2021

• By Joseph Haas

business — Organon continues growing its women's health portfolio with Forendo acquisition

Related Content

Forendo Pharma: Tackling The Endometriosis Challenge

Nov 10 2017

Merck & Co To Break New Ground With Female-Led Organon Unit

Mar 22 2021

Organon's First Move Post Spinout Is A Licensing Deal With ObsEva In Preterm Labor

Jul 27 2021

Organon Is Serious About Building A Women's Health Company, Deal By Deal

Jun 03 2021

Organon Is Ready To Launch And Makes The Case To Investors

May 03 2021

Related Companies

Merck & Co., Inc.

Organon

Forendo Pharma Oy

ObsEva SA

Alydia Health, Inc.

Additional Topics

M & A Business Strategies Deals Commercial Companies BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window